Skip to main content

Table 2 Univariate and multivariate logistic regression models evaluating the associations of dipyridamole-thallium scan with the rates of 90-day cardiac complications, 90-day mortality, and 1-year mortality

From: Does preoperative dipyridamole-thallium scanning reduce 90-day cardiac complications and 1-year mortality in patients with femoral neck fractures undergoing hemiarthroplasty?

Outcome Unmatched cohort Matched cohort  
Unadjusted OR (95% CI) p value Adjusted ORa (95% CI) p value Adjusted ORb (95% CI) p value
Overall 90-day cardiac complications 1.86 (1.11–3.13) 0.019 1.44 (0.71–2.91) 0.309 1.32 (0.75–2.33) 0.332
Unstable angina 6.52 (0.41–104) 0.186 4.26 (0.12–154) 0.429 3.02 (0.19–48.1) 0.437
Acute myocardial infarction 3.28 (0.59–18.1) 0.174 2.83 (0.38–21.2) 0.310 3.04 (0.42–21.3) 0.272
90-day mortality 0.92 (0.11–7.58) 0.941 9.80 (0.23–424.8) 0.235 0.75 (0.08–6.71) 0.797
1-year mortality 1.09 (0.57–2.08) 0.799 0.54 (0.24–1.20) 0.128 0.62 (0.27–1.42) 0.259
  1. aAdjusted for age, sex, body mass index, American Society of Anesthesiologists (ASA) grade, preoperative comorbidities (ischemic heart disease, congestive heart failure, valvular heart disease, cerebrovascular accident, diabetes, chronic obstructive pulmonary disease, rheumatoid arthritis, liver disease, renal disease, and cancer history), surgical variables (anesthesia and cemented stem, operative duration, and transfusion), and duration to surgery
  2. bAdjusted for ASA grade and ischemic heart disease
  3. OR odds ratio, CI confidence interval